Adocia
A89
Company Profile
Business description
Adocia is a clinical-stage biotechnology company focused on developing treatments for diabetes, obesity, and related metabolic diseases. The company uses its proprietary BioChaperone, AdoShell, AdOral and AdoXLong technology platforms to develop improved formulations of therapeutic proteins and peptides, oral and long-acting metabolic treatments, and immunoprotective cell-therapy solutions. Its pipeline includes BioChaperone Lispro, BioChaperone GLP-1 Amylin, AdoXLong Sema, AdOral Sema, AdoShell Islets and M1Pram.
Contact
115 Avenue Lacassagne
Lyon69003
FRAT: +33 472610610
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
82
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
stocks
Surge in combat drones drives upgrade for ASX share
Drone demand powers growth but investor optimism is overdone.
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
The market’s negative reaction to the announcement signals that investors, much like us, are not super excited about Meta’s prospects in the enterprise market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,854.70 | 60.30 | 0.69% |
| CAC 40 | 7,865.96 | 30.65 | 0.39% |
| DAX 40 | 25,151.36 | 212.01 | 0.85% |
| Dow JONES (US) | 50,926.56 | 20.51 | 0.04% |
| FTSE 100 | 10,440.19 | 11.92 | 0.11% |
| HKSE | 23,972.29 | 640.98 | -2.60% |
| NASDAQ | 26,871.60 | 10.53 | 0.04% |
| Nikkei 225 | 68,309.46 | 647.26 | -0.94% |
| NZX 50 Index | 13,680.49 | 130.02 | -0.94% |
| S&P 500 | 7,666.45 | 14.91 | 0.19% |
| S&P/ASX 200 | 8,682.10 | 67.70 | 0.79% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |